Effectiveness of nirsevimab in preventing RSV-hospitalisation among young children in Western Australia 2024
This study is the first Australian study to provide nirsevimab effectiveness estimate against RSV hospitalisation over a single epidemic season. The adjusted estimate of nirsevimab effectiveness against RSV-associated ARI hospitalisation was 88.2%, similar to those reported from Northern Hemisphere countries.
Authors
- Catherine Pienaar (ORCID: https://orcid.org/0000-0003-3679-8715)
- Hannah C. Moore (ORCID: https://orcid.org/0000-0001-6434-8290)
- Peter Richmond (ORCID: https://orcid.org/0000-0001-7562-7228)
- Allen Cheng (ORCID: https://orcid.org/0000-0003-3152-116X)
- Avram Levy (ORCID: https://orcid.org/0000-0002-0934-2387)
- Lana Bell (ORCID: https://orcid.org/0000-0003-2271-965X)
- Christopher C. Blyth (ORCID: https://orcid.org/0000-0003-2017-0683)
- Ushma Wadia (ORCID: https://orcid.org/0000-0002-8097-5072)
- Ciara Finucane
- John G. Harvey
- Lauren Bloomfield (ORCID: https://orcid.org/0000-0001-5890-4254)
- Paul V. Effler
- Erin van der Helder
Institutions
- The Kids Research Institute Australia (AU)
- The University of Western Australia (AU)
- Curtin University (AU)
- Princess Margaret Hospital for Children (AU)
- Fiona Stanley Hospital (AU)
- Government of Western Australia Department of Health (AU)
- Monash Health (AU)
- Pathwest Laboratory Medicine (AU)
- Perth Children's Hospital
- Monash University (AU)
- The University of Notre Dame Australia (AU)
Publication Details
- Journal
- Journal of Infection
- Published
- 2025-03-11
- DOI
- https://doi.org/10.1016/j.jinf.2025.106466
- Citations
- 22
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 29.79
Funders
- Children's Hospital Foundation
- Stan Perron Charitable Foundation
- National Health and Medical Research Council